Cargando…
Corrigendum: 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis
Autores principales: | Kennedy, Adam D., Pappan, Kirk L., Donti, Taraka, Delgado, Mauricio R., Shinawi, Marwan, Pearson, Toni S., Lalani, Seema R., Craigen, William J., Sutton, V. Reid, Evans, Anne M., Sun, Qin, Emrick, Lisa T., Elsea, Sarah H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001677/ https://www.ncbi.nlm.nih.gov/pubmed/32082103 http://dx.doi.org/10.3389/fnins.2019.01344 |
Ejemplares similares
-
2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis
por: Kennedy, Adam D., et al.
Publicado: (2019) -
Synthesis of New Optically Active 2-Pyrrolidinones
por: Moutevelis-Minakakis, Panagiota, et al.
Publicado: (2012) -
Succinimid of Mercury
por: Wright, B. L.
Publicado: (1916) -
Synthesis of
Functionalized Pyrrolidinone Scaffolds
via Smiles-Truce Cascade
por: Sephton, Thomas, et al.
Publicado: (2023) -
GABA transaminase deficiency. Case report and literature review
por: Oshi, Amira, et al.
Publicado: (2021)